Lilly shifts early-stage research to Indian JV

Eli Lilly has struck yet another key research collaboration deal. Anxious to push ahead with a slate of early-stage therapies, the pharma company struck a deal with India's Jubilant--a clinical research organization and manufacturer--to create a joint venture discovery firm. The JV will provide preclinical and early-stage discovery work, advancing therapies to Phase II testing before returning them for more advanced research work. While the new operation will do work for Jubilant and Eli Lilly, it will also offer research support to other companies as well.

"As in our discovery collaboration, we believe this unique partnership will be a pioneering effort in leveraging the expertise of a global pharmaceutical company like Lilly with the emerging development capabilities of Jubilant," said Jubilant's co-chairmen Shyam and Hari Bhartia.

- here's Jubilant's release
- read the report from in-Pharma Technologist

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.